Oral mucositis is one of the most frequent symptoms in cancer treatment or patients undergoing
stem cell transplantation,9 and this may influence long-term treatments negatively.10 Mucositis occurs one week after the onset of treatment and recovers in about 21 days.11 Therefore, oral mucosa needs to be protected as the treatment gets started.
Bretagne, "Real-time PCR for diagnosis and follow-up of Toxoplasma reactivation after allogeneic
stem cell transplantation using fluorescence resonance energy transfer hybridization probes," Journal of Clinical Microbiology, vol.
In conclusion, allogeneic
stem cell transplantation is a curative approach in many diseases.
Patients undergoing hematopoietic
stem cell transplantation require assistance with symptom control and for dealing with side effects in order to avoid negative effects of their physical condition, social/family status, emotional status, functional status, and additional detrimental effects on their quality of life.
Roh, "Human neural
stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage," Stroke, vol.
* The report provides a snapshot of the global therapeutic landscape of Hematopoietic
Stem Cell TransplantationTo carry out limbal
stem cell transplantation in various ocular surface disorders.
Finally, 29 patients received BM
stem cell transplantation, 100 patients were performed with peripheral blood
stem cell transplantation, and the other 6 patients' stem cells came from BM and peripheral blood.
As per the National Guidelines for Stem Cell Research 2013, stem cell therapy has not been proven effective other than in Hematopoietic
Stem Cell Transplantation ( HSCT) for haematological disorders ( disorders which primarily affect the blood).
Key words: Childhood, hematopoetic
stem cell transplantation, cord blood transplantation
It includes discussion of the rationale for transplantation, types, evaluation and counseling of patients and donors, preventative care, graft-versus-host disease, special transfusion-related situations, regulation and accreditation, and conditioning regimens, as well as a new chapter on oral health in
stem cell transplantation.
CliniMACS Biotec, Cambridge, MA and Bergisch Gladbach, Germany, announced the US Food and Drug Administration has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-versus-host disease (GvHD) in patients with acute myeloid leukemia (AMS) in first complete remission undergoing allogeneic
stem cell transplantation (SCT) from a matched related donor.